 | | |
Welcome to the xenoMED, an online Medical Community where Academically sound, Professionally conscious and Socially responsible Medical Students, Doctors & Health Professionals interact with each other globally.
Medicine is the only profession that incessantly tries to destroy its own existence. Howsoever you may be associated with basic and/or clinical medicine - student or professor, physician or surgeon, undergraduate or postgraduate - this is your place to share your knowledge, and learn more. Just get the message across!
You are currently viewing our communiy as a guest which gives you limited access to view most discussions and access our other features. By joining our free community you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, Join Our Medical Cummunity Today!
If you have any problems with the registration process or your account login, please contact us.
| | Member | | Posts: 38 Thanks: 0
Thanked 14 Times in 14 Posts
Join Date: Apr 2007 Location: kathmandu | | | FDA approve new drugs -
12-08-2007, 04:35 AM
FDA Approves First in New Class of HIV Drugs The FDA granted accelerated approval to the anti-HIV drug maraviroc (Selzentry) on August 6, making it the first commercially available agent in the class of CCR5 inhibitors. While other antiretroviral drugs fight HIV within white blood cells, maraviroc prevents the virus from entering uninfected cells by blocking the CCR5 coreceptor. The drug is indicated for treatment-experienced patients who have detectable HIV viral load, evidence of resistance to multiple existing drugs, and documented infection with CCR5-tropic virus. Roughly half of all extensively treatment-experienced HIV-infected patients have CCR5-tropic virus. Journal Watch HIV/AIDS Editor-in-Chief Paul E. Sax comments: "When given to patients who harbor CCR5-tropic, multidrug-resistant virus, maraviroc greatly augments treatment responses. In addition, it appears to have a very favorable safety profile." FDA press release (Free) Previous Journal Watch HIV/AIDS meeting report regarding maraviroc (Free) Share:  Digg this /  Add to del.icio.us /  Add to reddit /  Forward to a Friend | | Thread Tools | Search this Thread | | | | | Display Modes |  Linear Mode | 
Posting Rules
| You may not post new threads You may not post replies You may not post attachments You may not edit your posts
HTML code is Off | | | |
Powered by vBulletin® Version 3.7.3 Copyright ©2000 - 2008, Jelsoft Enterprises Ltd.
Content Relevant URLs by vBSEO 3.1.0
vBulletin Skin developed by: vBStyles.com
Copyright © 2005-2007 xenoMED, Kathmandu, Nepal
| Hosted and Maintained by:
 | |  | |
